Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma. (29th November 2012)

• Record Type: Journal Article
• Authors: Graceffa, D.; Maiani, E.; Pace, A.; Solivetti, F. M.; Elia, F.; De Mutiis, C.; Bonifati, C.
• Other Names: Cevik R. Academic Editor.; Salazar-Paramo M. Academic Editor.; Soy M. Academic Editor.
• Is Part Of: Case reports in rheumatology. Volume 2012(2012)
• Publication Date: 2012-11-29
• Subjects: Rheumatology -- Periodicals; Rheumatology -- Case studies -- Periodicals; Rheumatic Diseases; Connective Tissue Diseases; Rheumatology; Periodicals; Electronic journals; Case studies; Periodicals; 616.723
• DOI: 10.1155/2012/208606
• Languages: English
• ISSNs: 2090-6889

Abstract

Abstract : Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of severe psoriasis who developed psoriatic arthritis during a course of bevacizumab, which was administered for a malignant glioma.